Cara Therapeutics (CARA) : 4 analysts are covering Cara Therapeutics (CARA) and their average rating on the stock is 1, which is read as a Strong Buy. 4 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 4, which recommends a Sell affirms that they expect a large upside in the stock from the current levels.
Cara Therapeutics (CARA) : The highest level Cara Therapeutics (CARA) is projected to reach is $24 for the short term and the lowest estimate is at $16. The consolidated price target from 4 rating analysts who initiate coverage on the stock is $20.5 and the possibility the share price can swing is $4.12.
Cara Therapeutics Inc. has lost 4.77% in the last five trading days and dropped 1.48% in the last 4 weeks. Cara Therapeutics Inc. has dropped 3.23% during the last 3-month period . Year-to-Date the stock performance stands at -64.47%. Cara Therapeutics (NASDAQ:CARA): On Tuesdays trading session , Opening price of the stock was $6.1 with an intraday high of $6.12. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $5.925. However, the stock managed to close at $5.99, a loss of 1.16% for the day. On the previous day, the stock had closed at $6.06. The total traded volume of the day was 297,058 shares.
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the bodys peripheral nervous system. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. CR845 is a peripherally-acting kappa opioid receptor agonist for the treatment of both acute and chronic pain. I.V. CR845 is an injectable version of its peripheral kappa opioid receptor agonist, which is designed to provide pain relief without stimulating mu opioid receptors. CR701 is a peripherally-restricted, mixed-CB1/CB2 receptor agonist that interacts with these cannabinoid receptor subtypes, with no off-target activities.